A Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

A Phase 2b, Randomized, Double Blind, Vehicle Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Cream Applied Once or Twice Daily for 6 Weeks in Participants With Mild or Moderate Atopic Dermatitis

Category & Conditions:
Skin Diseases and Conditions
Medicine:
brepocitinib (PF-06700841)
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
B7931022
Open Plain Language Summary Result:Click here